Study Group: Diovan Prescribers: Cardiologists
Council Members in this Study Group: 57
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Mark Feinberg
Assistant Professor
HARVARD MEDICAL SCHOOL
Mark Feinberg, MD, is an Associate Physician and Principal Investigator in the Cardiovascular Division at Brigham and Women's Hospital and an Assistant Professor of Medicine at Harvard Medical School, Massachusetts. He has expertise in the management...
- Daniel Fisher
Cardiologist
NEW YORK UNIVERSITY (INC)Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....
- Dan Streja
Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, LOS ANGELESDan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA...
- Joshua Feuer
Owner
JOSHUA M FEUERJoshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
If it seems too good to be true...it probably is.
December 9, 2008
Analysis by: Joshua Feuer, Owner,Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.
-
December 8, 2008
Analysis by: Joshua Feuer, Owner,There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.
-
Outsourcing of compassionate use of drugs?
January 18, 2008
Analysis by: Dan Streja, Clinical Professor of Medicine,No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.
-
Niacin...it's deja vu all over again.
January 29, 2007
Analysis by: Joshua Feuer, Owner,An Old Cholesterol Remedy Is New Again | www.nytimes.com
1. Pfizer Inc, the pharmaceutical giant, halted late-stage trials of the HDL increasing drug torcetrapib after investigators discovered that it increased heart problems and increased death rates in the treated population.
2. Niacin, a B vitamin that increases HDL (the good cholesterol) up to 35%, has largely been ignored by physicians treating hypercholesterolemia and coronary heart disease because it is difficult to prescribe related to the common nuisance, but non-serious side effect of flushing.
3. Statins typically decrease LDL (the bad cholesterol) by 30-50% and cardiovascular events by about 30-40% but one analysis suggests that by decreasing LDL by 40% and increasing HDL by 30%, cardiovascular events could be decreased by 70%.
4. A large trial is underway to test this hypothesis comparing statin therapy alone with combination statin plus niacin therapy. -
Drug-eluting Versus Uncoated Stents
September 19, 2006
Analysis by: Daniel Fisher, Cardiologist,NEJM Articles on DES in MI | content.nejm.org
The lead articles from the New England Journal of Medicine 9/14/06 reviewed new data showing benefits when comparing sirolimus-eluting stents to uncoated stents and when comparing paclitaxil eluting stents to uncoated stents.
There was a significant reduction in target-vessel revascularization at one year with the sirolimus-eluting stents compared to uncoated stents.
There was a trend (not statistically significant) toward reduction of serious adverse cardiac events at one year with paclitaxil-eluting stents compared to uncoated stents.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Partner
- Owner
- President
- Physician - Division Head
- Principal